| 000 | 01037 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517222147.0 | ||
| 264 | 0 | _c20190729 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1365-2036 | ||
| 024 | 7 |
_a10.1111/apt.14649 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIngiliz, P | |
| 245 | 0 | 0 |
_aEditorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _c06 2018 |
||
| 300 |
_a1551-1552 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 | _aFatal Outcome |
| 650 | 0 | 4 | _aHepatitis B |
| 650 | 0 | 4 | _aHepatitis B e Antigens |
| 650 | 0 | 4 | _aHepatitis B, Chronic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aSeroconversion |
| 700 | 1 | _aCanbay, A | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 47 _gno. 11 _gp. 1551-1552 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/apt.14649 _zAvailable from publisher's website |
| 999 |
_c28506650 _d28506650 |
||